velaxin 25 mg tablety
egis pharmaceuticals plc, maďarsko - venlafaxín - 30 - antidepressiva
velaxin 50 mg tablety
egis pharmaceuticals plc, maďarsko - venlafaxín - 30 - antidepressiva
velaxin 37,5 mg tablety
egis pharmaceuticals plc, maďarsko - venlafaxín - 30 - antidepressiva
alventa 37,5 mg
krka, d.d., novo mesto, slovinsko - venlafaxín - 30 - antidepressiva
alventa 75 mg
krka, d.d., novo mesto, slovinsko - venlafaxín - 30 - antidepressiva
alventa 150 mg
krka, d.d., novo mesto, slovinsko - venlafaxín - 30 - antidepressiva
velaxin 37,5 mg tvrdé kapsuly s predĺženým uvoľňovaním
egis pharmaceuticals plc, maďarsko - venlafaxín - 30 - antidepressiva
velaxin 75 mg tvrdé kapsuly s predĺženým uvoľňovaním
egis pharmaceuticals plc, maďarsko - venlafaxín - 30 - antidepressiva
velaxin 150 mg tvrdé kapsuly s predĺženým uvoľňovaním
egis pharmaceuticals plc, maďarsko - venlafaxín - 30 - antidepressiva
lorviqua
pfizer europe ma eeig - lorlatinib - karcinóm, pľúc bez malých buniek - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.